COVID-19：RDIF、アビファビルの増産発表：35地域に配送（動画）：
RDIF increased production of Avifavir and begin export deliveries：
RDIF宣布增加用于治疗冠状病毒的阿维法韦的生产，并开始出口交货
COVID-19：
RDIFとChemRar：
治療薬アビファビルを100,000コースを量産しました。
2020年6月、アビファビルはロシアの35地域に、配送されています。
50カ国以上がアビファビルの輸入に関心を示しています
モスクワ、2020年7月2日-
ロシアの直接投資基金（RDIF）、
ロシアのソブリンウェルスファンド、ChemRarグループ
2020年6月、ロシアで。初のコロナウイルス薬アビファビル100,000コースを生産。
当初計画60,000コースの生産レベルを、大幅に上回りました。
2020年6月、治療薬はロシアの35地域とベラルーシ共和国に配送完了。
Agreement
has also been reached for deliveries of Avifavir to the Republic of Kazakhstan in the near future. In total, more than 100,000 courses will be produced in July.
The joint venture established by RDIF and ChemRar Group
provided an additional opportunity to increase production capacity threefold, up to 300,000 courses per month, which will satisfy domestic demand for Avifavir in the Russian Federation and enable the start of supplies to the international market.
On May 29, 2020, Avifavir
received a registration certificate from Russia’s Ministry of Health and became the first Favipiravir-based drug in the world approved for the treatment of COVID-19.
On June 3, 2020, the Ministry of Health
included Avifavir in the latest seventh edition of the guidelines for the prevention, diagnosis and treatment of new coronavirus infection COVID-19.
Avifavir has proven effective in clinical trials, disrupting the reproduction mechanisms of coronavirus.
RDIF and ChemRar
have seen significant demand for the drug from abroad. In particular, negotiations are underway on the supply of Avifavir to a number of Latin American countries.
In addition, CIS countries, the Middle East and other global regions have expressed interest in acquiring Avifavir.